Breast cancer brain metastases (BCBMs) are common in patients with advanced breast cancer diseases. This is one of the breast cancer subtypes and its performance status are the major determinants of the course of the disease and survival time following a diagnosis of brain metastasis. The unique challenges specific to the management of BCBMs includes, overcoming the blood-brain barrier (BBB) and resistance to conventional systemic therapies, as BCBMs typically occur in the pretreated patient population. The development of new systemic and selective targeting nanoformulation based therapies for BCBMs has become increasingly important. In this work, we developed a cisplatin prodrug loaded brain accumulating nanoparticle to deliver the active drug cisplatin to the mitochondria of the cancer cells. Though, the brain cell matrix is very complex and heterogeneous, we were able to show the selective targeting ability of these nanoparticles towards the BCBM cells over non-cancerous brain cells by crossing the BBB.

Selective targeting of breast cancer brain metastases by cisplatin prodrug nano-formulation

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.